ABSTRACT
PURPOSE: Breast cancers have a poorer prognosis if estrogen receptor expression was lost during recurrence. It is unclear whether this conversion is cell autonomous or whether it can be promoted by the microenvironment during cancer dormancy. We explored the ability of marrow-derived stromal cell lines to arrest co-cultured breast cancer cells and suppress estrogen receptor alpha (ER) expression during arrest, facilitating the emergence of estrogen-independent breast cancer clones. METHODS: Cancer cell growth, ER protein, microRNA, and mRNA levels were measured in breast cancer cell lines exposed to conditioned medium from marrow stromal lines in the presence and absence of estrogen and of signaling pathway modulators. RESULTS: We demonstrate that paracrine signaling from the stromal cell line HS5 downregulated ER in T47D and MCF7 breast cancer cells. This occurred at the mRNA level and also through decreased ER protein stability. Additionally, conditioned medium (CM) from HS5 arrested the breast cancer cells in G0/G1 in part through interleukin-1 (IL1) and inhibited cancer cell growth despite the activation of proliferative pathways (Erk and AKT) by the CM. Similar findings were observed for CM from the hFOB 1.19 osteoblastic cell line but not from two other fibroblastic marrow lines, HS27A and KM101. HS5-CM inhibition of MCF7 proliferation could not be restored by exogenous ER, but was restored by the IL1-antagonist IL1RA. In the presence of IL1RA, HS5-CM activation of AKT and Erk enabled the outgrowth of breast cancer cells with suppressed ER that were fulvestrant-resistant and estrogen-independent. CONCLUSIONS: We conclude that marrow-derived stromal cells can destabilize estrogen receptor protein to convert the ER status of growth-arrested ER+ breast cancer cell lines. The balance between stromal pro- and anti-proliferative signals controlled the switch from a dormant phenotype to estrogen-independent cancer cell growth.
Subject(s)
Breast Neoplasms/metabolism , Paracrine Communication , Receptors, Estrogen/metabolism , Stromal Cells/metabolism , Antineoplastic Agents, Hormonal/pharmacology , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cell Cycle Checkpoints/genetics , Cell Line, Tumor , Cell Proliferation , Drug Resistance, Neoplasm , Endoplasmic Reticulum/metabolism , Estradiol/analogs & derivatives , Estradiol/pharmacology , Estrogen Receptor alpha/metabolism , Exosomes/metabolism , Female , Fulvestrant , Gene Expression Regulation, Neoplastic , Humans , Interleukin-1/metabolism , MicroRNAs/genetics , Receptors, Estrogen/antagonists & inhibitors , Receptors, Estrogen/genetics , Signal Transduction , Stromal Cells/pathologyABSTRACT
Current vaccines primarily work by inducing protective antibodies. However, in many infections like HIV, malaria and tuberculosis as well as cancers, there remains a need for durable and protective T-cell immunity. Here, we summarize our efforts to develop a safe T-cell-based protein vaccine that exploits the pivotal role of dendritic cells (DC) in initiating adaptive immunity. Focusing on HIV, gag-p24 protein antigen is introduced into a monoclonal antibody (mAb) that efficiently and specifically targets the DEC-205 antigen uptake receptor on DC. When administered together with synthetic double-stranded RNA, polyriboinosinic:polyribocytidylic acid (poly IC) or its analogue poly IC stabilized with carboxymethylcellulose and poly-L-lysine (poly ICLC), as adjuvant, HIV gag-p24 within anti-DEC-205 mAb is highly immunogenic in mice, rhesus macaques, and in ongoing research, healthy human volunteers. Human subjects form both T- and B-cell responses to DC-targeted protein. Thus, DC-targeted protein vaccines are a potential new vaccine platform, either alone or in combination with highly attenuated viral vectors, to induce integrated immune responses against microbial or cancer antigens, with improved ease of manufacturing and clinical use.
Subject(s)
Dendritic Cells/immunology , Immunity, Cellular/immunology , T-Lymphocytes/immunology , Vaccines/immunology , Adjuvants, Immunologic/pharmacology , Animals , Antigens, CD/immunology , CD8-Positive T-Lymphocytes/immunology , Carboxymethylcellulose Sodium/analogs & derivatives , Carboxymethylcellulose Sodium/pharmacology , Gene Products, gag/immunology , Humans , Interferon Inducers/pharmacology , Lectins, C-Type/immunology , Mice , Minor Histocompatibility Antigens , Poly I-C/pharmacology , Polylysine/analogs & derivatives , Polylysine/pharmacology , Receptors, Cell Surface/immunology , Signal Transduction/immunology , Toll-Like Receptors/immunologyABSTRACT
We studied the central nervous system (CNS) of rhesus macaques during series of vaccination experiments in which attenuated simian immunodeficiency virus (SIV), SIVmac239Deltanef, was applied to the tonsils and the animals were later challenged with pathogenic SIVmac251 or SHIV/89.6P via tonsils or rectum. The pathologic lesions were graded on a scale of 0-5. The lesions were in general very mild, with a score of 0.5, except for one case, in which the animal had progressed to simian AIDS (SAIDS) and had severe lesions of grade 4. Except for the SAIDS case, the most common lesions were meningitis, ependymitis, inflammation of choroid plexus, and astrocytosis. Invasion of the challenge virus, SIVmac251, and pathologic lesions were detected 4 days post infection. The main features of the pathological lesions were similar during short-term follow-up (4 days to 2 weeks) and long-term follow-up (23 to 56 weeks) after challenge. No significant difference was found between unvaccinated controls infected with the challenge viruses and vaccinated and challenged animals. The pathological lesions in the one SAIDS case consisted of extensive lesions of the white matter in connection with confluent ependymitis, indicating an invasion through the choroid plexus. The lesions were characterized by a myriad of multinucleated giant cells of macrophage origin, which showed, together with individual macrophages, strong labelling for viral RNA and proteins. Productive infection of astrocytes was a very rare finding. In three cases infected via tonsils with SIVmac239Deltanef without challenge, we detected expression of Nef-derived peptides, indicating a selective pressure for Nef functions in the CNS.
Subject(s)
Brain/pathology , Immunity, Mucosal , Palatine Tonsil , SAIDS Vaccines/adverse effects , Simian Acquired Immunodeficiency Syndrome/prevention & control , Animals , Female , Genes, nef , Immunohistochemistry , In Situ Hybridization , Macaca mulatta , Male , Mucous Membrane , RNA, Viral/isolation & purification , SAIDS Vaccines/administration & dosage , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Immunodeficiency Virus , Vaccines, Attenuated/adverse effectsABSTRACT
This review addresses the scope of influence of mRNA decay on cellular functions and its potential role in normal and malignant hematopoiesis. Evidence is emerging that leukemic oncogenes and hematopoietic cytokines interact with mRNA decay pathways. These pathways can co-regulate functionally related genes through specific motifs in the 3'-untranslated region of targeted transcripts. The steps that link external stimuli to transcript turnover are not fully understood, but include subcellular relocalization or post-transcriptional modification of specific transcript-stabilizing or -destabilizing proteins. Improper functioning of these regulators of mRNA turnover can impede normal cellular differentiation or promote cancers. By delineating how subsets of transcripts decay in synchrony during normal hematopoiesis, it may be possible to determine whether this post-transcriptional regulatory pathway is hijacked in leukemogenesis.
Subject(s)
Hematopoiesis/genetics , Leukemia/genetics , RNA Stability , 3' Untranslated Regions , Animals , Cell Differentiation , Humans , Leukemia/etiology , Leukemia/pathology , RNA Processing, Post-TranscriptionalABSTRACT
The innate immune system provides many ways to quickly resist infection. The two best-studied defenses in dendritic cells (DCs) are the production of protective cytokines-like interleukin (IL)-12 and type I interferons-and the activation and expansion of innate lymphocytes. IL-12 and type I interferons influence distinct steps in the adaptive immune response of lymphocytes, including the polarization of T-helper type 1 (Th1) CD4+ T cells, the development of cytolytic T cells and memory, and the antibody response. DCs have many other innate features that do not by themselves provide innate resistance but are critical for the induction of adaptive immunity. We have emphasized three intricate and innate properties of DCs that account for their sentinel and sensor roles in the immune system: (1) special mechanisms for antigen capture and processing, (2) the capacity to migrate to defined sites in lymphoid organs, especially the T cell areas, to initiate immunity, and (3) their rapid differentiation or maturation in response to a variety of stimuli ranging from Toll-like receptor (TLR) ligands to many other nonmicrobial factors such as cytokines, innate lymphocytes, and immune complexes. The combination of innate defenses and innate physiological properties allows DCs to serve as a major link between innate and adaptive immunity. DCs and their subsets contribute to many subjects that are ripe for study including memory, B cell responses, mucosal immunity, tolerance, and vaccine design. DC biology should continue to be helpful in understanding pathogenesis and protection in the setting of prevalent clinical problems.
Subject(s)
Dendritic Cells/immunology , Animals , Antigen Presentation , Antigens/immunology , Antigens, CD/physiology , B-Lymphocytes/immunology , Cytokines/metabolism , Dendritic Cells/metabolism , Endocytosis , Humans , Immunity, Active , Immunity, Innate , Immunologic Memory , Receptors, Cell Surface , T-Lymphocytes/immunologyABSTRACT
Dendritic cells (DCs) are best known for their roles in host resistance and immunogenicity. DCs provide a direct link between innate and adaptive immunity. After antigen capture and processing, DCs control the differentiation and polarization of T cells. However, there is a danger during the antigen presentation because, at the same time DCs are capturing microbial antigens and also dying self cells and environmental proteins, to which the immune system must not respond. There is good evidence that immature DCs, in the absence of infection and inflammation, induce immunological tolerance to innocuous self antigens, avoiding then a non-appropriate response to harmless antigens that may be presented subsequently when infection strikes.
Subject(s)
Antigen Presentation/immunology , Dendritic Cells/immunology , Immune Tolerance/immunology , Animals , Autoantigens/immunology , Cell Differentiation , Humans , Infections/immunology , Self Tolerance/immunology , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/immunologyABSTRACT
Dendritic cells (DCs) can influence HIV-1 and SIV pathogenesis and protective mechanisms at several levels. First, HIV-1 productively infects select populations of DCs in culture, particularly immature DCs derived from blood monocytes and skin (Langerhans cells). However, there exist only a few instances in which HIV-1- or SIV-infected DCs have been identified in vivo in tissue sections. Second, different types of DCs reliably sequester and transmit infectious HIV-1 and SIV in culture, setting up a productive infection in T cells interacting with the DCs. This stimulation of infection in T cells may explain the observation that CD4+ T lymphocytes are the principal cell type observed to be infected with HIV-1 in lymphoid tissues in vivo. DCs express a C-type lectin, DC-SIGN/CD209, that functions to bind HIV-1 (and other infectious agents) and transmit virus to T cells. When transfected into the THP-1 cell line, the cytosolic domain of DC-SIGN is needed for HIV-1 sequestration and transmission. However, DCs lacking DC-SIGN (Langerhans cells) or expressing very low levels of DC-SIGN (rhesus macaque monocyte-derived DCs) may use additional molecules to bind and transmit immunodeficiency viruses to T cells. Third, DCs are efficient antigen-presenting cells for HIV-1 and SIV antigens. Infection with several recombinant viral vectors as well as attenuated virus is followed by antigen presentation to CD4+ and CD8+ T cells. An intriguing pathway that is well developed in DCs is the exogenous pathway for nonreplicating viral antigens to be presented on class I MHC products. This should allow DCs to stimulate CD8+ T cells after uptake of antibody-coated HIV-1 and dying infected T cells. It has been proposed that DCs, in addition to expanding effector helper and killer T cells, induce tolerance through T cell deletion and suppressor T cell formation, but this must be evaluated directly. Fourth, DCs are likely to be valuable in improving vaccine design. Increasing DC uptake of a vaccine, as well as increasing their numbers and maturation, should enhance efficacy. However, DCs can also capture antigens from other cells that are initially transduced with a DNA vaccine or a recombinant viral vector. The interaction of HIV-1 and SIV with DCs is therefore intricate but pertinent to understanding how these viruses disrupt immune function and elicit immune responses.
Subject(s)
Dendritic Cells/virology , HIV-1/physiology , T-Lymphocytes/virology , Animals , Antigen Presentation/immunology , Antigens, Viral/immunology , Biological Transport , Dendritic Cells/immunology , HIV Infections/immunology , HIV Infections/pathology , HIV Infections/virology , Humans , Monocytes/immunology , Simian Immunodeficiency Virus/physiology , T-Lymphocytes/immunology , VaccinationABSTRACT
The RADTRAN and RISKIND transportation risk analysis computer codes are the primary tools used to estimate dose consequences and risks associated with the transport of radioactive material. Over the years, some of the mathematical models used within the two computer codes have been updated and the methodologies to calculate input parameters have been improved. In addition, both codes have been evaluated for ease of use and appropriateness of application and verified against other computer codes that perform similar calculations. However, neither code has been validated against experimental data. This report discusses the results of five sets of experimental measurements used to partially validate the specific mathematical models used to predict the dose to an individual due to a passing shipment of radioactive material within the RADTRAN and RISKIND computer codes. Based on the comparisons it was found that RISKIND most closely predicted the measured dose in the majority of the investigated scenarios and that 12 out of 14 cases demonstrate the expected inverse relationship between the measured dose and the distance of closest approach. Only half of the data demonstrated the expected inverse relationship between dose and speed of travel.
Subject(s)
Radiometry , Transportation , Algorithms , Models, Theoretical , Monte Carlo Method , Motor Vehicles , Neutrons , Photons , Radiation Monitoring , SoftwareSubject(s)
Cancer Vaccines , Dendritic Cells/immunology , Dendritic Cells/metabolism , Immunotherapy/methods , Neoplasms/immunology , Neoplasms/prevention & control , Clinical Trials as Topic , Dendritic Cells/cytology , Humans , Models, Biological , Neoplasms/therapy , Phenotype , Plasmids/metabolism , T-Lymphocytes/metabolism , Treatment Outcome , VaccinationABSTRACT
The 'natural' temporal coordination of head and eye was examined as four subjects tapped a sequence of targets arranged in 3D on a worktable in front of them. The head started to move before the eye 48% of the time. Both the head and eye started to move 'simultaneously' (within 8 ms of each other) 37% of the time. The eye started to move before the eye only 15% of the time. Gaze-shifts required to perform the tapping task were relatively large, 68% of them were between 27 degrees and 57 degrees. Gaze-shifts were symmetrical. There were almost as many lefts as rights. Very little inter- or intra-subject variability was observed. These results were not expected on the basis of prior studies of head/eye coordination performed under less natural conditions. They also were not expected given the results of two rather similar, relatively natural, prior experiments. We conclude that more observations under natural conditions will have to be made before we understand why, when and how human beings coordinate head and eyes as they perform everyday tasks in the work-a-day world.
Subject(s)
Eye Movements/physiology , Head Movements/physiology , Psychomotor Performance/physiology , Humans , Observer Variation , Saccades/physiologyABSTRACT
DC-SIGN, a human C-type lectin, is expressed on the surface of dendritic cells (DC), while a closely related human gene, DC-SIGNR or L-SIGN, is found on sinusoidal endothelial cells of liver and lymph node. Both DC-SIGN and DC-SIGNR/L-SIGN can bind ICAM-3 and HIV gp120, and transmit HIV to susceptible cells in trans. Here, we report the cloning of five mouse genes homologous to human DC-SIGN and DC-SIGNR/L-SIGN. Only one gene, named mouse DC-SIGN, is highly expressed in DC, and is not found in a panel of mouse macrophage and lymphocyte cell lines. The other four genes, named mouse SIGNR1 (SIGN-Related gene 1), SIGNR2, SIGNR3 and SIGNR4, are expressed at lower levels in various cells according to RT-PCR and Northern blot analyses on RNA. All the genes of mouse DC-SIGN and SIGNRs map to adjacent regions of chromosome 8 A1.2-1.3. However, like human DC-SIGN, only the mouse DC-SIGN gene is closely juxtaposed to the CD23 gene, while the other four SIGNR genes are located close to each other in a neighboring region. mRNAs of mouse DC-SIGN and three SIGNR genes encode type II transmembrane proteins (DC-SIGN, 238 amino acids; SIGNR1, 325 amino acids; SIGNR3, 237 amino acids; SIGNR4, 208 amino acids), but the SIGNR2 gene only encodes a carbohydrate recognition domain (CRD) without a cytosolic domain and a transmembrane domain (SIGNR2, 178 amino acids). Amino acid sequence similarities between the CRD of human DC-SIGN and the mouse homologues are 67% for DC-SIGN, 69% for SIGNR1, 65% for SIGNR2, 68% for SIGNR3 and 70% for SIGNR4 respectively. However, the membrane proximal neck domains in the mouse genes are much shorter than their counterparts in human DC-SIGN and DC-SIGNR/L-SIGN. This family of mouse C-type lectins is therefore complex, but only one of the new genes, DC-SIGN, is juxtaposed to CD23 and is expressed at high levels in DC.
Subject(s)
Cell Adhesion Molecules , Dendritic Cells , Lectins, C-Type , Lectins/genetics , Mice/genetics , Receptors, Cell Surface/genetics , Amino Acid Sequence , Animals , Cloning, Molecular , DNA, Complementary , Humans , Lectins/isolation & purification , Molecular Sequence Data , Receptors, Cell Surface/isolation & purification , Receptors, IgE/genetics , Receptors, IgE/isolation & purification , Sequence Homology, Amino Acid , Spleen/cytology , Tissue DistributionABSTRACT
The p27Kip1 cell cycle inhibitor (p27) has emerged as a critical mediator of normal cellular growth control. We report the expression of a 24 kD C-terminal variant of p27 in normal peripheral blood lymphocytes. This variant is rapidly degraded in a proteasome-dependent manner when lymphocytes are activated by interleukin-2 or by superantigen. Whereas p24 degradation is complete within 16 h of mitogen addition, full-length p27 is decreased only modestly over 72 h of mitogen exposure and is present in activated and cycling lymphocytes. Persistent p27 is present in a complex with cyclin D3 in activated lymphocytes, and is localized both in the nucleus and cytoplasm. These results indicate that lymphocytes exiting from quiescence use several mechanisms to overcome the p27Kip1-enforced cell cycle checkpoint, and that elimination of p27 is not required for cell cycle entry.
Subject(s)
Cell Cycle Proteins/biosynthesis , Cell Cycle Proteins/chemistry , Lymphocytes/metabolism , Muscle Proteins , Tumor Suppressor Proteins/biosynthesis , Tumor Suppressor Proteins/chemistry , Blotting, Western , Cell Cycle , Cell Division , Cell Line , Cell Nucleus/metabolism , Cyclin D3 , Cyclin-Dependent Kinase Inhibitor p27 , Cyclins/metabolism , Cysteine Endopeptidases , Cytoplasm/metabolism , Down-Regulation , Fetal Blood/metabolism , Flow Cytometry , Humans , Lymphocyte Activation , Microfilament Proteins/metabolism , Microscopy, Confocal , Multienzyme Complexes/antagonists & inhibitors , Proteasome Endopeptidase Complex , Protein Binding , Protein Isoforms , Time Factors , Umbilical Cord/metabolismABSTRACT
Cellular differentiation frequently involves sequential peaks in the expression of cyclin-dependent kinase inhibitors (cdki's). For example, an increase in levels of the cdki p27Kip1 follows upregulation of p21Waf1 in several cell types induced to differentiate by diverse stimuli. In this study, we have investigated whether p21Waf1 expression itself, rather than the differentiating agent, could be increasing p27Kip1 protein levels. We used an inducible p21Waf1 expression vector in a K562 leukemic cell model which we had previously shown to initiate differentiation following p21Waf1 upregulation. The current study reports that p21Waf1 upregulated p27Kip1 protein without altering p27Kip1 mRNA levels. This effect did not depend on G1-phase arrest-the increase in p27Kip1 occurred at all phases of the cell cycle. p21Waf1-expressing extracts inhibited phosphorylation of p27Kip1 on threonine-187, leading to decreased ubiquitination and decreased proteasomal destruction of p27Kip1. In K562 cells, upregulation of p27Kip1 by p21Waf1 during differentiation facilitated an ordered transition between these two cdki's, each of which may distinctly influence the differentiation process.
Subject(s)
CDC2-CDC28 Kinases , Cell Cycle Proteins/metabolism , Cyclins/physiology , Proto-Oncogene Proteins , Tumor Suppressor Proteins , Cell Cycle , Cell Differentiation , Cell Extracts , Cyclin-Dependent Kinase 2 , Cyclin-Dependent Kinase 4 , Cyclin-Dependent Kinase Inhibitor p21 , Cyclin-Dependent Kinase Inhibitor p27 , Cyclin-Dependent Kinases/metabolism , Cyclins/genetics , Humans , K562 Cells , Phosphorylation , Protein Serine-Threonine Kinases/metabolism , Transfection , Up-RegulationABSTRACT
Dendritic cells (DCs) have the capacity to initiate immune responses, but it has been postulated that they may also be involved in inducing peripheral tolerance. To examine the function of DCs in the steady state we devised an antigen delivery system targeting these specialized antigen presenting cells in vivo using a monoclonal antibody to a DC-restricted endocytic receptor, DEC-205. Our experiments show that this route of antigen delivery to DCs is several orders of magnitude more efficient than free peptide in complete Freund's adjuvant (CFA) in inducing T cell activation and cell division. However, T cells activated by antigen delivered to DCs are not polarized to produce T helper type 1 cytokine interferon gamma and the activation response is not sustained. Within 7 d the number of antigen-specific T cells is severely reduced, and the residual T cells become unresponsive to systemic challenge with antigen in CFA. Coinjection of the DC-targeted antigen and anti-CD40 agonistic antibody changes the outcome from tolerance to prolonged T cell activation and immunity. We conclude that in the absence of additional stimuli DCs induce transient antigen-specific T cell activation followed by T cell deletion and unresponsiveness.
Subject(s)
Antigen Presentation/immunology , Dendritic Cells/immunology , Lectins, C-Type , Lymphocyte Activation/immunology , T-Lymphocytes/immunology , Animals , Antigens, CD/immunology , B7-2 Antigen , CD40 Antigens/immunology , Female , Lymphocytes/immunology , Membrane Glycoproteins/immunology , Mice , Mice, Inbred C57BL , Minor Histocompatibility Antigens , Muramidase/immunology , Receptors, Cell Surface/immunology , Spleen/cytologyABSTRACT
Immunization to multiple defined tumor antigens for specific immune therapy of human cancer has thus far proven difficult. Eighteen HLA A*0201(+) patients with metastatic melanoma received injections s.c. of CD34(+)progenitor-derived autologous dendritic cells (DCs), which included Langerhans cells. DCs were pulsed with peptides derived from four melanoma antigens [(MelAgs) MelanA/MART-1, tyrosinase, MAGE-3, and gp100], as well as influenza matrix peptide (Flu-MP) and keyhole limpet hemocyanin (KLH) as control antigens. Overall immunological effects were assessed by comparing response profiles using marginal likelihood scores. DC injections were well tolerated except for progressive vitiligo in two patients. DCs induced an immune response to control antigens (KLH, Flu-MP) in 16 of 18 patients. An enhanced immune response to one or more MelAgs was seen in these same 16 patients, including 10 patients who responded to >2 MelAgs. The two patients failing to respond to both control and tumor antigens experienced rapid tumor progression. Of 17 patients with evaluable disease, 6 of 7 patients with immunity to two or less MelAgs had progressive disease 10 weeks after study entry, in contrast to tumor progression in only 1 of 10 patients with immunity to >2 MelAgs. Regression of >1 tumor metastases were observed in seven of these patients. The overall immunity to MelAgs after DC vaccination is associated with clinical outcome (P = 0.015).
Subject(s)
Antigens, CD34/immunology , Cancer Vaccines/immunology , Cancer Vaccines/therapeutic use , Dendritic Cells/immunology , Melanoma/immunology , Melanoma/therapy , Adult , Aged , Antigens, Neoplasm/immunology , CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/adverse effects , Female , HLA-A2 Antigen/immunology , Hemocyanins/immunology , Humans , Hypersensitivity, Delayed/immunology , Immunotherapy, Adoptive/methods , Langerhans Cells/immunology , Male , Middle Aged , Treatment OutcomeSubject(s)
Antigen Presentation , Antigens/immunology , Antigens/metabolism , Dendritic Cells/cytology , Dendritic Cells/immunology , Animals , Cell Differentiation , Endocytosis , Histocompatibility Antigens/immunology , Histocompatibility Antigens/metabolism , Immune Tolerance/immunology , Signal Transduction , T-Lymphocytes/immunologyABSTRACT
BACKGROUND: Low levels of the cyclin-dependent kinase inhibitor p27Kip1 are associated with poor prognosis in cancer. It is unclear whether this is related strictly to p27Kip1-mediated cell cycle inhibition or to other, possibly extranuclear, roles of this protein. In this study, we examined p27Kip1 expression in quiescent and activated lymphocytes. T-cell membranes have been shown to possess sphingolipid and cholesterol-rich microdomains that are insoluble in non-ionic detergents. These "rafts" provide a scaffold for signaling proteins. Signal transduction coincides with coalescence of these microdomains into larger complexes. METHODS: Localization of p27Kip1 was studied by electron and confocal microscopy. Association of p27Kip1 with membrane microdomains in unstimulated and stimulated lymphocytes was determined using Western blots analysis of isolated membranes variably treated with detergents. RESULTS: We demonstrated that p27Kip1 was present in clusters associated with the plasma membrane in normal lymphocytes. The solubility profile of p27Kip1 in isolated membranes indicated that it was localized to raft structures. When lymphocytes were stimulated, however, p27Kip1 was excluded from aggregated raft complexes. CONCLUSIONS: This study identifies, for the first time, the localization of p27 within a membrane microdomain associated with signaling. Because some cell surface signaling complexes lose p27Kip1 upon cellular activation, p27Kip1 may play a functional role in modulating membrane signaling.
Subject(s)
Cell Cycle Proteins/metabolism , Cell Membrane/metabolism , Detergents/pharmacology , T-Lymphocytes/metabolism , Tumor Suppressor Proteins , Antigens, CD/metabolism , Antigens, Differentiation, T-Lymphocyte/metabolism , CD59 Antigens/metabolism , Cell Membrane/chemistry , Cell Membrane/drug effects , Cyclin-Dependent Kinase Inhibitor p27 , Detergents/chemistry , Humans , Lectins, C-Type , Lymphocyte Activation , Octoxynol/pharmacology , Solubility , T-Lymphocytes/chemistry , T-Lymphocytes/drug effectsABSTRACT
BACKGROUND: Relevant antigens often are known for diseases that involve the immune system. Yet purified antigens by themselves do not control immunity, especially T-cell immunity. For example, many antigens have been defined for HIV-1 and melanoma, but good HIV-1 vaccines and melanoma immune therapies are lacking. Dendritic cells (DCs) are important intermediaries between antigens and better control of the immune system. METHODS: Some properties that allow DCs to control immunity are reviewed, followed by new studies using DCs as adjuvants in humans. An emerging area is then detailed, the special mechanisms whereby DCs enhance the formation of ligands for T-cells, i.e., complexes of major histocompatibility complex (MHC) products and antigenic peptides. RESULTS: Once criteria were developed to identify and isolate DCs, several functional properties became evident. DCs are unusually potent in initiating T-cell mediated immunity in culture. In vivo, DCs are positioned to capture antigens and migrate to T-cell areas of lymphoid organs. There, DCs are able to prime animals, controlling the MHC restriction of the primed T-cells and inducing resistance to pathogens. DCs pulsed ex vivo with antigens are now being used to induce and expand T-cell immunity in humans. To optimize their use, two areas of DC function need to be harnessed: their terminal differentiation or maturation, and antigen uptake. DCs capture most types of antigens at an immature stage of development, but the cells must receive additional stimuli prior to acquiring potent T-cell stimulatory activity. Stimuli from microbes, inflammation and trauma mature DCs. These change the DCs in several ways, even inducing the formation of MHC II-peptide complexes or T-cell receptor (TCR) ligands. The latter move to the surface in nonlysosomal vesicles that simultaneously carry CD86 costimulatory molecules for T-cell activation. Both MHC and CD86 remain co-clustered in patches at the DC surface. DCs also express a receptor, DEC-205, that enhances antigen uptake and presentation. DEC-205 recycles in an unusual manner through MHC class II-rich, late endosomes or lysosomes, dramatically increasing the presentation of bound ligands. Additionally and importantly, DCs can process dying cells and immune complexes onto MHC class I products, events that are termed the "exogenous pathway" or "cross presentation." CONCLUSIONS: The control of the immune system by DCs reflects numerous specializations, not a single "magic bullet." These specializations include a number of mechanisms that increase the efficiency of antigen uptake and MHC-peptide complex formation. The harnessing of these and other features of DCs provides opportunities for improving immune-based therapies and vaccine design.
Subject(s)
Antigen Presentation/immunology , Dendritic Cells/immunology , Major Histocompatibility Complex/immunology , Humans , Immunity, Cellular , Immunotherapy/methods , T-Lymphocytes/immunologyABSTRACT
Immunostimulatory properties of dendritic cells (DCs) are linked to their maturation state. Injection of mature DCs rapidly enhances antigen-specific CD4+ and CD8+ T cell immunity in humans. Here we describe the immune response to a single injection of immature DCs pulsed with influenza matrix peptide (MP) and keyhole limpet hemocyanin (KLH) in two healthy subjects. In contrast to prior findings using mature DCs, injection of immature DCs in both subjects led to the specific inhibition of MP-specific CD8+ T cell effector function in freshly isolated T cells and the appearance of MP-specific interleukin 10-producing cells. When pre- and postimmunization T cells were boosted in culture, there were greater numbers of MP-specific major histocompatibility complex tetramer-binding cells after immunization, but these had reduced interferon production and lacked killer activity. These data demonstrate the feasibility of antigen-specific inhibition of effector T cell function in vivo in humans and urge caution with the use of immature DCs when trying to enhance tumor or microbial immunity.